论文部分内容阅读
目的 分析恩替卡韦联合聚乙二醇干扰素α-2a 治疗慢性乙型肝炎的效果?方法 选择2018年3月至2019年3月我院收治的90例慢性乙型肝炎患者，采用随机数字表法将所有患者分成观察组与对照组，每组45例?对照组采用恩替卡韦治疗，观察组采用恩替卡韦联合聚乙二醇干扰素α-2a 治疗，对比两组治疗效果?结果 观察组的总有效率80.00% 高于对照组的57.78%，差异具有统计学意义(P<0.05)?治疗6 个月后观察组的HBV DNA 转阴率?ALT 复常率?HBeAg 转阴率高于对照组，差异具有统计学意义(P<“,”Objective To analyze the effect of entecavir combined with polyethylene glycol interferon α-2a in the treatment of chronic hepatitis B.Methods Ninety patients with chronic hepatitis B from March 2018 to March 2019 were selected，and all patients were divided into observation group and control group with 45 cases.The control group was treated with entecavir and the observation group was treated with entecavir combined with polyethylene glycol interferon α-2a.Results The total effective rate of 80.00% was higher than the control group\'s 57.78%，and the difference was statistically signi?cant (P<0.05).After 6 months of treatment，HBV DNA revulsion rate，ALT relapse rate and HBeAg revulsion rate were higher in the observation group than in the control group，the difference was statistically signi?cant (P<0.05).The difference was statistically signi?cant in the observation group after 12 months with HBV DNA revulsion，ALT revulsion and HBeAg revulsion compared with the control group (P0.05).Conclusion Enticavir combined with polyethylene glycol interferon α-2a is effective in the treatment of chronic hepatitis B.It is safe and reliable，and is worth promoting and applying.